Drug Profile
Collagenase clostridium histolyticum - BioSpecifics Technologies Corporation/Endo International
Alternative Names: AA-4500; AK-160; CCH; Clostridial collagenase; Collagenase clostridium histolyticum-aaes; Cordase; EN-3835; PF-5076985; Plaquase; Qwo; XIAFLEX; XiapexLatest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator BioSpecifics Technologies Corporation
- Developer Actelion Pharmaceuticals; Asahi Kasei; BioSpecifics Technologies Corporation; Endo International; Swedish Orphan Biovitrum
- Class Antineoplastics; Collagenases; Skin disorder therapies; Urologics
- Mechanism of Action Collagenase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cellulite; Dupuytren's contracture; Peyronie's disease
- Phase III Fibroma
- Phase II Frozen shoulder; Lipoma
- No development reported Breast disorders; Metabolic disorders; Uterine leiomyoma
- Discontinued Hypertrophic scars; Keloids; Tendon injuries
Most Recent Events
- 02 Feb 2024 Endo Pharmaceuticals initiates phase III STRIDE trial for Fibroma (Intralesional) in USA (NCT06151197)
- 05 Dec 2023 Endo Pharmaceuticals plans a phase II trial for Plantar fasciitis (Intrafacial, Injection) in December 2023 (NCT06169319)
- 30 Nov 2023 Endo Pharmaceuticals plans a phase III STRIDE trial for Fibroma (Intralesional) in November 2023 , (NCT06151197)